NewsMeter

Eli Lilly posts $23 billion Q2 as Mounjaro, Zepbound carry GLP-1 lead over Viking Therapeutics

8/9/2026

$23 billion in second-quarter revenue, a 48% year-over-year gain reported by Eli Lilly (NYSE: LLY), anchors the company's case as the GLP-1 market's commercial leader.

The math reconciles: tirzepatide generated $14.8 billion across its two approved brands, with Mounjaro (diabetes) at $9.9 billion, up 91% YoY, and Zepbound (weight management) at $4.9 billion, up 46% YoY.

Viking Therapeutics (NASDAQ: VKTX), the most prominently cited challenger, has no approved products and no revenue.

Tirzepatide's approved reach and what comes next Tirzepatide, a dual GLP-1 and GIP hormone agonist, holds approvals for type 2 diabetes, weight loss, and obstructive sleep apnea.